Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 4/20 | 1.00 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | RAB9A | P51151 | 4/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 3/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PPARG | P37231 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | CASP3 | P42574 | 2/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14269503 | 0.85 | CYP19A1 (0.74) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| Trifluoromethanesulfonic Acid SCHEMBL27954027 | 0.84 | CYP19A1 (0.71) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL17422783 | 0.84 | CYP19A1 (0.71) | CYP19A1IDO1FFAR1ESR1 | |
| SCHEMBL17422937 | 0.83 | CYP19A1 (0.71) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL10173132 | 0.82 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL21812464 | 0.82 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL26670118 | 0.82 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL30751168 | 0.82 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL6585488 | 0.82 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AKDM4EMEN1 | |
| SCHEMBL2243728 | 0.82 | CYP19A1 (0.70) | CYP19A1NPC1RAB9AKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113201526-B | Difunctional photo-enzyme synergistic catalyst and preparation method and application thereof | 东南大学 | 2024-04-09 | — | — | CN | claimed |
| CN-109400518-B | Polysubstituted 6-arylbenzo [ a ] carbazole derivative and synthetic method thereof | 湘潭大学 | 2021-09-24 | — | — | CN | claimed |
| CN-113201526-A | Bifunctional photo-enzyme synergistic catalyst and preparation method and application thereof | 东南大学 | 2021-08-03 | — | — | CN | claimed |
| WO-2025201477-A1 | SPIROCYCLIC GSDME INHIBITORS | PYROTECH (BEIJING) BIOTECHNOLOGY CO.,LTD. (CN) | 2025-10-02 | — | — | WO | disclosed |
| CN-119977949-A | Chromone bisindole derivative and preparation method and application thereof | 重庆文理学院 | 2025-05-13 | — | — | CN | disclosed |
| CN-113196511-B | Organic electroluminescent device and spiro compound for organic electroluminescent device | 三星显示有限公司 | 2025-01-14 | — | — | CN | disclosed |
| US-20240431203-A1 | ORGANIC ELECTROLUMINESCENCE DEVICE AND SPIRO COMPOUND FOR ORGANIC ELECTROLUMINESCENCE DEVICE | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-12-26 | — | — | US | disclosed |
| US-12108667-B2 | Organic electroluminescence device and spiro compound for organic electroluminescence device | SAMSUNG DISPLAY CO., LTD. (KR) | 2024-10-01 | — | — | US | disclosed |
| CN-113201526-B | Difunctional photo-enzyme synergistic catalyst and preparation method and application thereof | 东南大学 | 2024-04-09 | — | — | CN | disclosed |
| CN-115304533-A | Bis-indole methane type alpha-glucosidase inhibitor and preparation method and application thereof | 中国医学科学院药用植物研究所云南分所 | 2022-11-08 | — | — | CN | disclosed |
| CN-110272370-B | Synthesis method of trifluoromethyl substituted 3,3' -bis (2-phenylindolyl) methane compound | 福州大学 | 2022-08-23 | — | — | CN | disclosed |
| WO-2013009126-A2 | COMPOUND FOR AN ORGANIC ELECTRONIC DEVICE, AND ORGANIC ELECTRONIC DEVICE AND ELECTRONIC APPARATUS USING SAME | 덕산하이메탈(주) (KR) | 2013-01-17 | — | — | WO | disclosed |
| WO-2013009126-A2 | COMPOUND FOR AN ORGANIC ELECTRONIC DEVICE, AND ORGANIC ELECTRONIC DEVICE AND ELECTRONIC APPARATUS USING SAME | 덕산하이메탈(주) (KR) | 2013-01-17 | — | — | WO | disclosed |
| EP-2460791-A1 | INDOLE DERIVATIVE AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF | Kissei Pharmaceutical Co., Ltd. (JP) | 2012-06-06 | — | — | EP | disclosed |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2012-05-24 | — | — | US | disclosed |
| US-7473786-B1 | Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473786-B1 | Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| US-7473786-B1 | Methods and systems for preparing fused heterocyclic compounds using copper(I) catalysts | UNIVERSITY OF MASSACHUSETTS (US) | 2009-01-06 | — | — | US | disclosed |
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | NIPPON SHINYAKU CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452525-A1 | AMIDE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014942-A1 | Transforming growth factor inhibitor; controllign cell differentiation, cell proliferation | TGFBR1, TGFBR2, TGFB1 | CYP19A1 3073/4885NPC1 1944/4885RAB9A 4031/4885 |
| US-20120129890-A1 | INDOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF | PTGER1, CYSLTR1, ARRB1 | CYP19A1 1214/4885NPC1 1234/4885RAB9A 2053/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.